Screening for safe harbor sites in the genome may improve the safety of gene therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Papapetrou, E.P. et al. Nat. Biotechnol. 29, 73–78 (2011).
Felice, B. et al. PLoS ONE 4, e4571 (2009).
Cattoglio, C. et al. Blood published online, doi:10.1182/blood-2010–05–283523 (23 September 2010).
Cavazzana-Calvo, M. et al. Nature 467, 318–322 (2010).
Hockemeyer, D. et al. Nat. Biotechnol. 27, 851–857 (2009).
Perez, E.E. et al. Nat. Biotechnol. 26, 808–816 (2008).
DeKelver, R.C. et al. Genome Res. 20, 1133–1142 (2010).
Henckaerts, E. et al. Proc. Natl. Acad. Sci. USA 106, 7571–7576 (2009).
Takahashi, K. & Yamanaka, S. Cell 126, 663–676 (2006).
Hanna, J. et al. Science 318, 1920–1923 (2007).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Williams, D., Thrasher, A. Out of harm's way. Nat Biotechnol 29, 41–42 (2011). https://doi.org/10.1038/nbt.1750
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.1750